WESTMINSTER, Colo., Aug. 12, 2013 (GLOBE NEWSWIRE) -- GeneThera, Inc. (OTCBB:GTHR) is commenting on the recent news about a massive recall of infant milk formula announced by Fonterra, Inc. The recall involves 7 countries, including China; one of Fonterra's largest markets and was triggered by the discovery of a lethal strain of the bacterium Clostridium Botulinum in contaminated whey products.

GeneThera, Inc., a molecular diagnostic and Biotechnology Company, is presently working with Otakaro Patways, Ltd., a research and development company based in Christchurch, to set up an advanced molecular diagnostic laboratory in New Zealand for the rapid detection of bacterial pathogens in milk and other dairy products. Otakaro Patways delivers services to agriculture and horticulture industries in New Zealand. Fonterra, a New Zealand based company, is the largest exporter of dairy products in the world with revenues in excess of NZ$19B and the largest company in the country.

Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., stated: "Fonterra recall is once again a clear proof of how devastating and costly food recall may be. In this particular case, the recall is even more dramatic because it involves milk products that are used in infant formulas. GeneThera has spent several years developing state-of-the-art technology in collaboration with one of the world's largest equipment companies, to test milk products by using the most advanced integrated laboratory robotic platform that allows the detection of Mycobacterium Paratuberculosis and Tuberculosis in a very high, sensitive, and fast way. This technology platform can also be employed for the detection of other infection pathogens.

We are fully confident that the implementation of such technology could help companies such as Fonterra to minimize or prevent critical situations, as the one they are presently facing."

About GeneThera, Inc.

GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES and Johne's disease management system, HERDCHECK™, designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES and HERDCHECK™ systems are designed for a host of individual diseases, the current priority being Johne's disease. For more information concerning GeneThera's technology, contact Dr. Tony Milici at 720- 439-3011.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

CONTACT: For further information, please contact: Casey Burt, Managing Partner Mirador Consulting, LLC 561-989-3600Source:GeneThera